Biologic therapies in inflammatory bowel disease

Steven J. Brown, Maria T Abreu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) is considered to arise in genetically predisposed individuals as a result of a dysregulated immune response to the luminal bacteria (1). Advances in our understanding of the many factors that contribute to mucosal immune dysregulation have resulted in the development of a number of new therapies for this complex disorder. These 'biologics' specifically target defective pathways in the immune response and are either currently in use or on the horizon for use in IBD. It is crucial that clinicians on the front lines of treating patients have an understanding of both the basic pathogenesis of IBD and the mechanisms of action of the new biologic therapies in order to rationally prescribe them and to deal with their potential toxicities. This review aims to briefly discuss these factors and highlight the most promising of the new biologic therapies that have been examined in IBD.

Original languageEnglish
Pages (from-to)38-63
Number of pages26
JournalPractical Gastroenterology
Volume29
Issue number7
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Biological Therapy
Inflammatory Bowel Diseases
Biological Products
Bacteria
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Biologic therapies in inflammatory bowel disease. / Brown, Steven J.; Abreu, Maria T.

In: Practical Gastroenterology, Vol. 29, No. 7, 01.07.2005, p. 38-63.

Research output: Contribution to journalArticle

Brown, Steven J. ; Abreu, Maria T. / Biologic therapies in inflammatory bowel disease. In: Practical Gastroenterology. 2005 ; Vol. 29, No. 7. pp. 38-63.
@article{2ce695137c3b479892da0bf563a1c56e,
title = "Biologic therapies in inflammatory bowel disease",
abstract = "Inflammatory bowel disease (IBD) is considered to arise in genetically predisposed individuals as a result of a dysregulated immune response to the luminal bacteria (1). Advances in our understanding of the many factors that contribute to mucosal immune dysregulation have resulted in the development of a number of new therapies for this complex disorder. These 'biologics' specifically target defective pathways in the immune response and are either currently in use or on the horizon for use in IBD. It is crucial that clinicians on the front lines of treating patients have an understanding of both the basic pathogenesis of IBD and the mechanisms of action of the new biologic therapies in order to rationally prescribe them and to deal with their potential toxicities. This review aims to briefly discuss these factors and highlight the most promising of the new biologic therapies that have been examined in IBD.",
author = "Brown, {Steven J.} and Abreu, {Maria T}",
year = "2005",
month = "7",
day = "1",
language = "English",
volume = "29",
pages = "38--63",
journal = "Practical Gastroenterology",
issn = "0277-4208",
publisher = "Shugar Publishing Inc.",
number = "7",

}

TY - JOUR

T1 - Biologic therapies in inflammatory bowel disease

AU - Brown, Steven J.

AU - Abreu, Maria T

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Inflammatory bowel disease (IBD) is considered to arise in genetically predisposed individuals as a result of a dysregulated immune response to the luminal bacteria (1). Advances in our understanding of the many factors that contribute to mucosal immune dysregulation have resulted in the development of a number of new therapies for this complex disorder. These 'biologics' specifically target defective pathways in the immune response and are either currently in use or on the horizon for use in IBD. It is crucial that clinicians on the front lines of treating patients have an understanding of both the basic pathogenesis of IBD and the mechanisms of action of the new biologic therapies in order to rationally prescribe them and to deal with their potential toxicities. This review aims to briefly discuss these factors and highlight the most promising of the new biologic therapies that have been examined in IBD.

AB - Inflammatory bowel disease (IBD) is considered to arise in genetically predisposed individuals as a result of a dysregulated immune response to the luminal bacteria (1). Advances in our understanding of the many factors that contribute to mucosal immune dysregulation have resulted in the development of a number of new therapies for this complex disorder. These 'biologics' specifically target defective pathways in the immune response and are either currently in use or on the horizon for use in IBD. It is crucial that clinicians on the front lines of treating patients have an understanding of both the basic pathogenesis of IBD and the mechanisms of action of the new biologic therapies in order to rationally prescribe them and to deal with their potential toxicities. This review aims to briefly discuss these factors and highlight the most promising of the new biologic therapies that have been examined in IBD.

UR - http://www.scopus.com/inward/record.url?scp=23744510266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744510266&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 38

EP - 63

JO - Practical Gastroenterology

JF - Practical Gastroenterology

SN - 0277-4208

IS - 7

ER -